Search
5th Focus in Paediatric Haematology-Oncology
The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…
Read moreStatement
The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…
Read moreChairs and Members
ChairGiancarlo Castaman, University of Florence - Careggi University Hospital, Florence (Italy)
Co-chairAnna Falanga, University of Milan Bicocca and Hospital Papa Giovanni XXIII, Bergamo (Italy)
SWG Steering Committee
Ajay K Kakkar, Thrombosis Research Institute, London (United Kingdom)
Augusto Federici, University of Milan, University Hospital Luigi…
EHA-SAH Hematology Tutorial on Acute Leukemia, MDS and BMF
Dates: September 11-12, 2020
Location: Buenos Aires, Argentina
Chairs: G Stemmelin, G Ossenkoppele
The third EHA-SAH Hematology Tutorial will be held in Buenos Aires, Argentina.
Congratulations to the 2021 Research Grant winners!
The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.
Read moreSponsor opportunities
EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…
Read moreGenome sequencing of thousands of patients with rare blood disorders
Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.
Read moreDaratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study
Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.
Read more